leisure time -WSS

leisure time

author：comprehensive 2025-09-03 05:38:09 - browse：34476

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Medicare details structure of new drug price negotiation program

knowledge

WSS

The biotech scorecard for Q1: 17 stock

AdventHealth escalates lawsuit against insurance vendor Multiplan

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Federal weight loss drug coverage is 30 years out of date

In Memoriam: Notable people who died in 2023

Sports medicine is finally prioritizing gender equality

focus

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

explore

In age of alternative facts, a scholarly course on calling out crap

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Wildfire smoke exposes gaps in outdoor worker protections

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The FDA must approve intranasal treatments for anaphylaxis

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Tori Bowie and the unacceptable rates of Black maternal death

Novavax promises a turnaround & Lilly roils the obesity market

How to save PrEP access — and even expand it

Wikipedia

At least 13 dead in Texas as scorching temps continue

Sports medicine is finally prioritizing gender equality

United colonoscopy coverage change 'may cost lives,' doctors say

New weight loss drugs work. But how can they best be used?

Affirmative action in medical school literally saved lives

Medical records are filled with copy

hotspot

knowledge

leisure time

Wikipedia